Literature DB >> 10741621

Assessment and reporting of clinical pharmacology information in drug labeling.

D A Spyker1, E D Harvey, B E Harvey, A M Harvey, B H Rumack, C C Peck, A J Atkinson, R L Woosley, D R Abernethy, L R Cantilena.   

Abstract

Mesh：

Year:  2000        PMID： 10741621     DOI： 10.1067/mcp.2000.104737

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  8 in total

Review 1.  The product label: how pharmacokinetics and pharmacodynamics reach the prescriber.

Authors:  Patrick J Marroum; Jogarao Gobburu
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management?

Authors:  Meret Martin-Facklam; Jens Rengelshausen; Yorki Tayrouz; Nahal Ketabi-Kiyanvash; Heike Lindenmaier; Verena Schneider; Verena Bergk; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2004-12-14       Impact factor: 2.953

3.  Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.

Authors:  J Reis-Pardal; A Rodrigues; E Rodrigues; F Fernandez-Llimos
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

Review 4.  Cytochrome P450 interactions and clinical implication in rheumatology.

Authors:  Audrey Cayot; Davy Laroche; Anne Disson-Dautriche; Anaïs Arbault; Jean-Francis Maillefert; Paul Ornetti
Journal:  Clin Rheumatol       Date:  2014-06-14       Impact factor: 2.980

5.  Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature.

Authors:  Verena Bergk; Walter E Haefeli; Christiane Gasse; Hermann Brenner; Meret Martin-Facklam
Journal:  Eur J Clin Pharmacol       Date:  2005-06-28       Impact factor: 2.953

6.  Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies.

Authors:  P Bonnabry; J Sievering; T Leemann; P Dayer
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

8.  Natural language processing-based assessment of consistency in summaries of product characteristics of generic antimicrobials.

Authors:  Rumiko Shimazawa; Yoshinobu Kano; Masayuki Ikeda
Journal:  Pharmacol Res Perspect       Date:  2018-11-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.